Khan, 50 patient vitamin D early treatment RCT: 33% improved recovery [p=0.15] and 50% improved viral clearance [p=0.009] https://c19p.org/khan4
copied to clipboard
Oral co-supplementation of curcumin, quercetin and vitamin D3 as adjuvant therapy for mild to moderate symptoms of COVID-19 -Results from an open-label, pilot randomized controlled trial
et al., Frontiers in Pharmacology
RCT 50 COVID+ outpatients in Pakistan, 25 treated with curcumin, quercetin, and vitamin D, showing significantly faster viral clearance, significantly improved CRP, and faster resolution of acute symptoms (p=0.154). Only the abstract is currently available. 168mg curcumin, 260mg quercetin and 360IU cholecalciferol.
|
risk of no recovery, 33.3% lower, RR 0.67, p = 0.15, treatment 10 of 25 (40.0%), control 15 of 25 (60.0%), NNT 5.0.
|
|
relative CRP reduction, 39.1% better, RR 0.61, p = 0.006, treatment 25, control 25.
|
|
risk of no viral clearance, 50.0% lower, RR 0.50, p = 0.009, treatment 10 of 25 (40.0%), control 20 of 25 (80.0%), NNT 2.5.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Khan et al., 5/1/2022, Randomized Controlled Trial, Pakistan, South Asia, peer-reviewed, 7 authors, this trial uses multiple treatments in the treatment arm (combined with curcumin and quercetin) - results of individual treatments may vary.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.